640 results on '"Michel Burnier"'
Search Results
2. Hypertension as Cardiovascular Risk Factor in Chronic Kidney Disease
- Author
-
Michel Burnier and Aikaterini Damianaki
- Subjects
Physiology ,Cardiology and Cardiovascular Medicine - Abstract
Hypertension is the leading modifiable cause of premature death and hence one of the global targets of World Health Organization for prevention. Hypertension also affects the great majority of patients with chronic kidney disease (CKD). Both hypertension and CKD are intrinsically related, as hypertension is a strong determinant of worse renal and cardiovascular outcomes and renal function decline aggravates hypertension. This bidirectional relationship is well documented by the high prevalence of hypertension across CKD stages and the dual benefits of effective antihypertensive treatments on renal and cardiovascular risk reduction. Achieving an optimal blood pressure (BP) target is mandatory and requires several pharmacological and lifestyle measures. However, it also requires a correct diagnosis based on reliable BP measurements (eg, 24-hour ambulatory BP monitoring, home BP), especially for populations like patients with CKD where reduced or reverse dipping patterns or masked and resistant hypertension are frequent and associated with a poor cardiovascular and renal prognosis. Even after achieving BP targets, which remain debated in CKD, the residual cardiovascular risk remains high. Current antihypertensive options have been enriched with novel agents that enable to lower the existing renal and cardiovascular risks, such as SGLT2 (sodium-glucose cotransporter-2) inhibitors and novel nonsteroidal mineralocorticoid receptor antagonists. Although their beneficial effects may be driven mostly from actions beyond BP control, recent evidence underline potential improvements on abnormal 24-hour BP phenotypes such as nondipping. Other promising novelties are still to come for the management of hypertension in CKD. In the present review, we shall discuss the existing evidence of hypertension as a cardiovascular risk factor in CKD, the importance of identifying hypertension phenotypes among patients with CKD, and the traditional and novel aspects of the management of hypertensives with CKD.
- Published
- 2023
3. Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations
- Author
-
Michel Burnier, Josep Redon, and Massimo Volpe
- Subjects
Internal Medicine ,Cardiology and Cardiovascular Medicine - Published
- 2023
4. Renal denervation in the antihypertensive arsenal – knowns and known unknowns
- Author
-
Franz H. Messerli, Chirag Bavishi, Jana Brguljan, Michel Burnier, Stephan Dobner, Fernando Elijovich, Keith C. Ferdinand, Sverre Kjeldsen, Cheryl L. Laffer, C. Venkata S Ram, Emrush Rexhaj, Luis M. Ruilope, Evgeniya V. Shalaeva, George C.M. Siontis, Jan A. Staessen, Stephen C. Textor, Wanpen Vongpatanasin, Liffert Vogt, Massimo Volpe, Jiguang Wang, Bryan Williams, Nephrology, ACS - Microcirculation, and APH - Health Behaviors & Chronic Diseases
- Subjects
CHRONIC KIDNEY-DISEASE ,hypertension ,Physiology ,Kidney ,antihypertensive treatment ,OBSTRUCTIVE SLEEP-APNEA ,Internal Medicine ,Humans ,Sympathectomy ,renal denervation ,Antihypertensive Agents ,UNCONTROLLED HYPERTENSION ,PAROXYSMAL ATRIAL-FIBRILLATION ,Science & Technology ,refractory hypertension ,SYMPLICITY HTN-3 ,AMBULATORY BLOOD-PRESSURE ,blood pressure ,Denervation ,BAROREFLEX ACTIVATION THERAPY ,Treatment Outcome ,Peripheral Vascular Disease ,Cardiovascular System & Cardiology ,SYMPATHETIC DENERVATION ,HEART-FAILURE ,TREATMENT-RESISTANT HYPERTENSION ,610 Medizin und Gesundheit ,Cardiology and Cardiovascular Medicine ,Life Sciences & Biomedicine - Abstract
Even though it has been more than a decade since renal denervation (RDN) was first used to treat hypertension and an intense effort on researching this therapy has been made, it is still not clear how RDN fits into the antihypertensive arsenal. There is no question that RDN lowers blood pressure (BP), it does so to an extent at best corresponding to one antihypertensive drug. The procedure has an excellent safety record. However, it remains clinically impossible to predict whose BP responds to RDN and whose does not. Long-term efficacy data on BP reduction are still unconvincing despite the recent results in the SPYRAL HTN-ON MED trial; experimental studies indicate that reinnervation is occurring after RDN. Although BP is an acceptable surrogate endpoint, there is complete lack of outcome data with RDN. Clear indications for RDN are lacking although patients with resistant hypertension, those with documented increase in activity of the sympathetic system and perhaps those who desire to take fewest medication may be considered. ispartof: JOURNAL OF HYPERTENSION vol:40 issue:10 pages:1859-1875 ispartof: location:Netherlands status: published
- Published
- 2022
5. Gout and hyperuricaemia: modifiable cardiovascular risk factors?
- Author
-
Michel Burnier
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Gout and hyperuricaemia are two clinical situations associated with an elevated risk of developing cardiovascular (heart failure, myocardial infarction, stroke) and metabolic and renal complications. One reason is probably related to the fact that the prevalence of hyperuricaemia and gout is high in clinical situations, which themselves involve a high cardiovascular risk, such as hypertension, diabetes, chronic kidney disease or obesity. However, recent studies suggest that hyperuricaemia may promote cardiovascular complications independently of other cardiovascular risk factors, by inducing chronic inflammation, oxidative stress, and endothelial dysfunction. The questions that arise today concern primarily the treatment of asymptomatic hyperuricaemia. Should it be treated to decrease the patients' cardiovascular risk and if so, starting from which level and towards which target? There are now several pieces of evidence indicating that this might be useful, but data from large studies are not unanimous. This review will discuss this issue as well as new well-tolerated treatments, such as febuxostat or SGLT2 inhibitors, which lower uric acid levels, prevent gout and lower the risk of cardio-renal events.
- Published
- 2023
6. Magnetic Resonance Imaging to Diagnose and Predict the Outcome of Diabetic Kidney Disease—Where Do We Stand?
- Author
-
Menno Pruijm, Ibtisam Aslam, Bastien Milani, Wendy Brito, Michel Burnier, Nicholas M. Selby, and Jean-Paul Vallée
- Abstract
Diabetic kidney disease (DKD) is a major public health problem and its incidence is rising. The disease course is unpredictable with classic biomarkers, and the search for new tools to predict adverse renal outcomes is ongoing. Renal magnetic resonance imaging (MRI) now enables the quantification of metabolic and microscopic properties of the kidneys such as single-kidney, cortical and medullary blood flow, and renal tissue oxygenation and fibrosis, without the use of contrast media. A rapidly increasing number of studies show that these techniques can identify early kidney damage in patients with DKD, and possibly predict renal outcome. This review provides an overview of the currently most frequently used techniques, a summary of the results of some recent studies, and our view on their potential applications, as well as the hurdles to be overcome for the integration of these techniques into the clinical care of patients with DKD.
- Published
- 2022
7. High blood pressure screening in pharmacies during May Measurement Month campaigns in Switzerland
- Author
-
Aikaterini Damianaki, Kenji Theiler, Thomas Beaney, Wei Wang, Michel Burnier, and Grégoire Wuerzner
- Subjects
Male ,Pharmacies ,Hypertension ,Internal Medicine ,Humans ,Blood Pressure ,Blood Pressure Determination ,Female ,General Medicine ,Cardiology and Cardiovascular Medicine ,Switzerland - Abstract
May Measurement Month (MMM) is an international screening campaign for arterial hypertension (HT) organised by the International Society of Hypertension and the World Hypertension League. It aims at raising the awareness of elevated blood pressure (BP) in the population. The goal of this analysis was to assess the results obtained in Swiss pharmacies during a 3-year campaign.Swiss data from the MMM17 to MMM19 campaigns were extracted from the global MMM database. The analysis was conducted specifically on measures taken in pharmacies. BP and a questionnaire including demographical and clinical information were recorded for each participant. To assess BP control, ESH 2018 thresholds of140/90 mmHg and ESH 2021 pharmacy-thresholds of135/85 mmHg were used.From an initial sample of 3634 Swiss participants included during this 3-year campaign, 2567 participants (73.2%women and 26.8% men,HT screening campaigns in pharmacies recruits mainly women. It helps the detection of untreated hypertensive participants and uncontrolled treated participants. Our data suggest that the average BP should be calculated on the second and third measurements due to a significant first measure effect in pharmacies measurement. SummaryHigh blood pressure (BP) is a major global public health issue as the leading risk factor of global death.World-wide initiatives like May Measurement Month (MMM) aim to screen thousands of people each year to raise awareness of hypertension (HT).Switzerland participated in MMM 2017-2019 and screened more than 2500 participants in pharmacies.When adopting the recent proposed thresholds of HT diagnosis in pharmacies (ESH 2021 135/85 mmHg), HT prevalence in Switzerland is high (38.3%) with only 2/3 of treated hypertensive achieving the BP goals.Women are more likely to participate in such campaigns taking place in pharmacies.A first measurement effect (FME) was also present in pharmacies, highlighting that taking three BP measurements in pharmacies and discarding the first should be also considered in the pharmacy setting.Involving a routine pharmacy-based health care of patients would help to identify more hypertensive patients and uncontrolled treated patients, who may not have had access to BP measurement.
- Published
- 2022
8. Women’s health, cardiovascular risk and hypertension: the perspective still needs to improve
- Author
-
Michel Burnier, Jana Brguljan, Engi Abd Elhady Algharably, Sverre E. Kjeldsen, Krzysztof Narkiewicz, Brent Egan, Suzanne Oparil, and Reinhold Kreutz
- Subjects
Internal Medicine ,General Medicine ,Cardiology and Cardiovascular Medicine - Published
- 2023
9. Renal Denervation: A Practical Guide for Health Professionals Managing Hypertension
- Author
-
Roland Schmieder, Michel Burnier, Cara East, Konstantinos Tsioufis, and Sean Delaney
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Growing evidence demonstrates the suitability of renal denervation in a broad population of patients; however, questions remain over its suitability and practical implementation. Given the rapidity of emerging data, this has been a challenging field for potential adopters to navigate. The purpose of this article is twofold: to provide navigation through emerging clinical data and evolving guidance; and to provide physicians with practical, evidence-based advice for identifying eligible patients and providing appropriate management in the pre- and postintervention settings. Although many of these recommendations are based on existing published guidance documents, we reflect equally on our own experiences of using this technology.
- Published
- 2023
10. Masked hypertension in type 2 diabetes: never take normotension for granted and always assess out-of-office blood pressure
- Author
-
Krzysztof Narkiewicz, Sverre E. Kjeldsen, Brent M. Egan, Reinhold Kreutz, and Michel Burnier
- Subjects
Diabetes Mellitus, Type 2 ,Masked Hypertension ,Hypertension ,Internal Medicine ,Humans ,Blood Pressure ,General Medicine ,Blood Pressure Monitoring, Ambulatory ,Cardiology and Cardiovascular Medicine ,White Coat Hypertension - Published
- 2022
11. Prevalence and Factors Associated with Opioid Prescription in Swiss Chronic Hemodialysis Patients
- Author
-
Clémence Hennebel, Valérie Vilmont, Anne Cherpillod, David Fumeaux, Fadi Fakhouri, Françoise Livio, Michel Burnier, and Menno Pruijm
- Subjects
end-stage kidney disease ,hemodialysis ,pain ,opioids - Abstract
Pain is a common symptom in patients on chronic hemodialysis (HD) but the prevalence of opioid prescriptions in this population has been poorly studied outside the United States. This study assesses the prevalence of opioid prescription in two Swiss dialysis centers. Prescriptions and clinical characteristics were retrospectively retrieved from the medical records of patients on HD for at least six months, treated at Lausanne University Hospital (academic center, AC), and the private center Clinique Cecil (PC) for the study. A total of 117 patients were included; 29.1% received at least one opioid prescription during the study period. Significantly more patients received an opioid prescription in the AC (39.1%) than in the PC (14.6%, p = 0.004). Univariate logistic regression analysis showed that center (Odds Ratio (OR) 3.76; Confidence Interval (CI) 1.48–9.6; p = 0.006), neuropathic pain (OR 2.99; CI 1.28–6.98; p = 0.011), benzodiazepine prescription (OR 2.72; CI 1.14–6.46; p = 0.024), polyneuropathy (OR 2.71; CI 1.14–6.46; p = 0.024) and amputation (OR 4.23; CI 1.1–16.1; p = 0.034) were associated with opioid prescription. The center was the only independent predictive factor in the multivariate analysis. Our results show that opioids are regularly prescribed to Swiss dialysis patients, although important differences exist between centers. The latter finding might suggest that opioid prescribing is more related to the prescriber than to the patient’s condition, but larger-scale studies are necessary to confirm this.
- Published
- 2022
12. Hypertension
- Author
-
Pascal Bovet, Alta E. Schutte, Nick Banatvala, and Michel Burnier
- Published
- 2023
13. Dietary salt and NCDs
- Author
-
Pascal Bovet, Michel Burnier, Nick Banatvala, and Leo Nederveen
- Published
- 2023
14. Improving the Management of Hypertension by Tackling Awareness, Adherence, and Clinical Inertia: A Symposium Report
- Author
-
Reinhold Kreutz, Michael Kavanagh, Atul Pathak, Michel Burnier, and Neil R Poulter
- Subjects
medicine.medical_specialty ,Cardiac & Cardiovascular Systems ,IMPACT ,SOCIETY ,Cardiology ,Review Article ,GUIDELINES ,THERAPY ,MEDICATION NONADHERENCE ,Elevated systolic blood pressure ,Humans ,Medicine ,Pharmacology (medical) ,Pharmacology & Pharmacy ,SELF-MANAGEMENT ,HEALTHY ,1102 Cardiorespiratory Medicine and Haematology ,Antihypertensive Agents ,Therapeutic inertia ,Science & Technology ,Hypertension control ,business.industry ,General Medicine ,EUROPEAN-SOCIETY ,PREVALENCE ,Key factors ,Cardiovascular System & Hematology ,Family medicine ,Hypertension ,Cardiovascular System & Cardiology ,Cardiology and Cardiovascular Medicine ,business ,Life Sciences & Biomedicine - Abstract
Hypertension remains the leading cause of global mortality, with elevated systolic blood pressure (BP) leading to 10.8 million deaths each year. Despite this, only around 50% of individuals with hypertension are aware of their condition. Alongside low awareness rates, lack of patient adherence to medication and therapeutic inertia have been identified as factors contributing to the lack of hypertension control worldwide. This report summarizes presentations from the “one of a kind” Servier-sponsored symposium, Improving the Management of Hypertension: Acting on Key Factors, which was conducted as part of the European Society of Hypertension (ESH)-International Society of Hypertension (ISH) 2021 ON-AIR meeting. The symposium focused on how low awareness, therapeutic inertia, and nonadherence can be addressed by combining the experience of a patient with the expertise of physicians. May Measurement Month, the ongoing global BP measurement program, is raising awareness of hypertension in over 90 countries, and the 2018 European Society of Cardiology/ESH guidelines and the 2020 ISH guidelines now include recommendations that specifically address low adherence and therapeutic inertia, including involving patients in a shared decision-making process and the use of single-pill combination therapy. Understanding the role of emotion in decision making and addressing the different psychological states and attitudes in the patient’s “cycle of change” are key to effective shared decision making and improving adherence. Supplementary Information The online version contains supplementary material available at 10.1007/s40256-021-00505-6., Plain Language Summary Raised blood pressure (hypertension) is involved in the death of around 10.8 million people throughout the world each year. However, only about half of the people with hypertension are aware of their condition. In addition, many patients who are prescribed blood pressure-lowering medications do not take their pills regularly (intentional or nonintentional low adherence). Many doctors are not as strict as they should be in ensuring blood pressure control of their hypertensive patients (therapeutic inertia). This report presents ideas and data from a “first of its kind” symposium sponsored by Servier as part of the European Society of Hypertension (ESH)-International Society of Hypertension (ISH) 2021 ON-AIR meeting involving both patient and physicians. The report summarizes the ways in which low awareness, therapeutic inertia, and lack of adherence can be addressed and includes insights into patients’ perspectives. An ongoing global blood pressure screening program called May Measurement Month was discussed, which has detected almost a million people with untreated or inadequately treated hypertension worldwide since 2017. Recent ESH and ISH guidelines for managing hypertension now include recommendations on how to address low adherence and therapeutic inertia. Crucially, doctors should involve their patients with hypertension in decisions about their own treatment, which will help improve adherence to medication and ultimately reduce hypertension-related serious adverse events (e.g. heart attacks, strokes and deaths). Supplementary Information The online version contains supplementary material available at 10.1007/s40256-021-00505-6.
- Published
- 2021
15. TIME to face the reality about evening dosing of antihypertensive drugs in hypertension
- Author
-
Sverre E. Kjeldsen, Brent M. Egan, Krzysztof Narkiewicz, Reinhold Kreutz, Michel Burnier, Suzanne Oparil, and Giuseppe Mancia
- Subjects
Humans ,Antihypertensive Agents ,Hypertension/drug therapy ,Blood Pressure ,Circadian Rhythm ,Hypertension ,Internal Medicine ,General Medicine ,Cardiology and Cardiovascular Medicine - Published
- 2022
16. Sex differences in the occurrence and reporting of adverse drug reactions in hypertension: What are the clinical implications?
- Author
-
Michel Burnier
- Subjects
Male ,Sex Characteristics ,Drug-Related Side Effects and Adverse Reactions ,Hypertension ,Humans ,Female ,Cardiology and Cardiovascular Medicine ,Medical History Taking - Published
- 2022
17. Key questions regarding the SYMPLICITY HTN-3 trial
- Author
-
Sverre E Kjeldsen, Michel Burnier, Krzysztof Narkiewicz, Reinhold Kreutz, and Giuseppe Mancia
- Subjects
General Medicine - Published
- 2023
18. The five RADIANCE-HTN and SPYRAL-HTN randomised studies suggest that the BP lowering effect of RDN corresponds to the effect of one antihypertensive drug
- Author
-
Suzanne Oparil, Michel Burnier, Sverre E. Kjeldsen, and Krzysztof Narkiewicz
- Subjects
Denervation ,medicine.medical_specialty ,business.industry ,medicine.drug_class ,Blood Pressure ,General Medicine ,Kidney ,Treatment Outcome ,Blood pressure ,Treatment modality ,Internal medicine ,Hypertension ,Internal Medicine ,Cardiology ,Humans ,Medicine ,Sympathectomy ,Cardiology and Cardiovascular Medicine ,business ,Antihypertensive drug ,Antihypertensive Agents - Abstract
Renal denervation (RDN) may be a new treatment modality for patients with hypertension. Initially, efforts to test the efficacy of RDN in lowering blood pressure (BP) have focussed on patients with...
- Published
- 2021
19. Missing Verification of Source Data in Hypertension Research: The HYGIA PROJECT in Perspective
- Author
-
Suzanne Oparil, Giuseppe Mancia, Krzysztof Narkiewicz, Reinhold Kreutz, Mattias Brunström, Sverre E. Kjeldsen, Knut Gjesdal, and Michel Burnier
- Subjects
Source data ,business.industry ,medicine.medical_treatment ,Perspective (graphical) ,Internal Medicine ,medicine ,business ,Data science ,Chronotherapy (treatment scheduling) - Published
- 2021
20. Accuracy of blood pressure measurement across BMI categories using the OptiBP™ mobile application
- Author
-
Mary Caillat, Jean Degott, Arlene Wuerzner, Martin Proençain, Guillaume Bonnier, Jean-François Knebel, Chloé Stoll, Urvan Christen, Virginie Durgnat, Gregory Hofmann, Michel Burnier, Grégoire Wuerzner, and Patrick Schoettker
- Subjects
Hypertension ,Internal Medicine ,Humans ,Blood Pressure ,Blood Pressure Determination ,General Medicine ,Obesity ,Overweight ,Cardiology and Cardiovascular Medicine ,Mobile Applications ,Body Mass Index - Abstract
Obesity is a clear risk factor for hypertension. Blood pressure (BP) measurement in obese patients may be biased by cuff size and upper arm shape which may affect the accuracy of measurements. This study aimed to assess the accuracy of the OptiBP smartphone application for three different body mass index (BMI) categories (normal, overweight and obese).Participants with a wide range of BP and BMI were recruited at Lausanne University Hospital's hypertension clinic in Switzerland. OptiBP estimated BP by recording an optical signal reflecting light from the participants' fingertips into a smartphone camera. Age, sex and BP distribution were collected to fulfil the AAMI/ESH/ISO universal standards. Both auscultatory BP references and OptiBP BP were measured and compared using the simultaneous opposite arms method, as described in the 81060-2:2018 ISO norm. Subgroup analyses were performed for each BMI category.We analyzed 414 recordings from 95 patients: 34 were overweight and 15 were obese. The OptiBP application had a performance acceptance rate of 82%. The mean and standard deviation (SD) differences between the optical BP estimations and the auscultatory reference rates (criterion 1) were respected in all subgroups: SBP mean value was 2.08 (SD 7.58); 1.32 (6.44); -2.29 (5.62) respectively in obese, overweight and normal weight subgroup. For criterion 2, which investigates the precision errors on an individual level, the threshold for systolic BP in the obese group was slightly above the requirement for this criterion.This study demonstrated that the OptiBP application is easily applicable to overweight and obese participants. Differences between the reference measure and the OptiBP estimation were within ISO limits (criterion 1). In obese participants, the SD of mean error was outside criterion 2 limits. Whether auscultatory measurement, due to arm morphology or the OptiBP is associated with increasing bias in obese still needs to be studied.What is the context? • Hypertension and obesity have a major impact on population health and costs. • Obesity is a chronic disease characterized by abnormal or excessive fat accumulation. • Obesity, in combination with other diseases like hypertension, is a major risk factor for cardiovascular and total death. • In Europe, the obesity rate is 21.5% for men and 24.5% for women. • Hypertension, which continues to increase in the population, is a factor that can be modified when well managed. • Blood pressure measurement by the usual method may be complicated in obese patients due to fat accumulation and the shape of the arm and can lead to measurement errors. In addition, the non-invasive blood pressure measurement can be constraining and uncomfortable.What is new? • Smartphone apps are gradually appearing and allow the measurement of blood pressure without a pressure cuff using photoplethysmography. • OptiBP is a smartphone application that provides an estimate of blood pressure that has been evaluated in the general population. • The objective of this study is to assess whether OptiBP is equally effective in obese and overweight patients.What is the impact? • The use of smartphones to estimate BP in overweight and obese patients may be a solution to the known bias associated with cuff measurement. • The acquisition of more and more data with a larger number of patients will allow the continuous improvement of the application’s algorithm.
- Published
- 2022
21. May Measurement Month 2017-2019: results from Switzerland
- Author
-
Aikaterini Damianaki, Wei Wang, Thomas Beaney, Thilo Burkard, Isabella Sudano, Michel Burnier, Gregoire Wuerzner, University of Zurich, and Wuerzner, Gregoire
- Subjects
10209 Clinic for Cardiology ,610 Medicine & health ,Cardiology and Cardiovascular Medicine ,2705 Cardiology and Cardiovascular Medicine - Abstract
May Measurement Month (MMM) is an international screening campaign for arterial hypertension initiated by the International Society of Hypertension and endorsed by the World Hypertension League. Its aim is to raise the awareness of elevated blood pressure (BP) in the population worldwide. The goal of the present analyses is to assess the results obtained during three years of this campaign in Switzerland. Swiss data from MMM17 to MMM19 campaigns were used. BP and a questionnaire for basic demographic and clinical information were recorded for each participant. BP measurements and definition of arterial hypertension followed the standard MMM protocol. To assess BP control, European Society of Hypertension 2018 thresholds of
- Published
- 2022
22. Defining intradialytic hypertension: the importance of measuring blood pressure accurately
- Author
-
Grégoire Wuerzner, Menno Pruijm, and Michel Burnier
- Subjects
Transplantation ,Nephrology - Published
- 2022
23. Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension
- Author
-
Paul Muntner, Anastasios Kollias, Paul L. Padfield, Jonathan Mant, George S. Stergiou, Juan Eugenio Ochoa, Richard J McManus, Martino F Pengo, Thomas Mengden, James E. Sharman, Satoshi Hoshide, Geoff Head, G. Mancia, Stefano Omboni, A. de la Sierra, Cristina Giannattasio, Anastasia S. Mihailidou, William B. White, Agustin J. Ramirez, Kazuomi Kario, Paolo Palatini, Angeliki Ntineri, Michael A. Weber, Ji-Guang Wang, Kei Asayama, Eoin O'Brien, Rajiv Agarwal, Y. Imai, R. Asmar, José A. Octavio, Nicolas Postel-Vinay, Martin G. Myers, Grzegorz Bilo, Jirar Topouchian, Efstathios Manios, Camilla Torlasco, Andrew Shennan, Gianfranco Parati, Egle Silva, Paul K. Whelton, Y. Li, Philippe Gosse, Takayoshi Ohkubo, Dario Pellegrini, Teemu J. Niiranen, Michel Burnier, Parati, G, Stergiou, G, Bilo, G, Kollias, A, Pengo, M, Ochoa, J, Agarwal, R, Asayama, K, Asmar, R, Burnier, M, De La Sierra, A, Giannattasio, C, Gosse, P, Head, G, Hoshide, S, Imai, Y, Kario, K, Li, Y, Manios, E, Mant, J, Mcmanus, R, Mengden, T, Mihailidou, A, Muntner, P, Myers, M, Niiranen, T, Ntineri, A, O'Brien, E, Octavio, J, Ohkubo, T, Omboni, S, Padfield, P, Palatini, P, Pellegrini, D, Postel-Vinay, N, Ramirez, A, Sharman, J, Shennan, A, Silva, E, Topouchian, J, Torlasco, C, Wang, J, Weber, M, Whelton, P, White, W, and Mancia, G
- Subjects
cardiovascular risk ,CHRONIC KIDNEY-DISEASE ,2019-20 coronavirus outbreak ,hypertension ,Coronavirus disease 2019 (COVID-19) ,blood pressure measurement ,Physiology ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,MEDLINE ,ORTHOSTATIC HYPOTENSION ,TARGET-ORGAN DAMAGE ,Blood Pressure ,MEDICAL INSTRUMENTATION/EUROPEAN SOCIETY ,cardiovascular disease ,SELF-MEASUREMENT ,Internal Medicine ,medicine ,Humans ,prevention and control ,Blood pressure monitoring ,Hypertension diagnosis ,Societies, Medical ,Science & Technology ,business.industry ,Blood Pressure Determination ,Blood Pressure Monitoring, Ambulatory ,medicine.disease ,WHITE-COAT HYPERTENSION ,home blood pressure monitoring ,PROGNOSTIC VALUE ,Blood pressure ,Peripheral Vascular Disease ,MEASURING DEVICES ,Hypertension ,Cardiovascular System & Cardiology ,Position paper ,Medical emergency ,FOLLOW-UP ,Cardiology and Cardiovascular Medicine ,business ,Life Sciences & Biomedicine ,OUTCOME-DRIVEN THRESHOLDS ,blood pressure monitorign, home, methodology - Abstract
The present paper provides an update of previous recommendations on Home Blood Pressure Monitoring from the European Society of Hypertension (ESH) Working Group on Blood Pressure Monitoring and Cardiovascular Variability sequentially published in years 2000, 2008 and 2010. This update has taken into account new evidence in this field, including a recent statement by the American Heart association, as well as technological developments, which have occurred over the past 20 years. The present document has been developed by the same ESH Working Group with inputs from an international team of experts, and has been endorsed by the ESH. ispartof: JOURNAL OF HYPERTENSION vol:39 issue:9 pages:1742-1767 ispartof: location:Netherlands status: published
- Published
- 2021
24. Single-pill combinations, hypertension control and clinical outcomes: potential, pitfalls and solutions
- Author
-
Brent M. Egan, Sverre E. Kjeldsen, Krzysztof Narkiewicz, Reinhold Kreutz, and Michel Burnier
- Subjects
Drug Combinations ,Hypertension ,Internal Medicine ,Humans ,Blood Pressure ,General Medicine ,Cardiology and Cardiovascular Medicine ,Antihypertensive Agents ,Tablets - Published
- 2022
25. Thirty years with LIFE-a randomized clinical trial with more than 200 published articles on clinical aspects of left ventricular hypertrophy
- Author
-
Sverre E. Kjeldsen, Brent M. Egan, Krzysztof Narkiewicz, Reinhold Kreutz, Michel Burnier, and Suzanne Oparil
- Subjects
Hypertension ,Internal Medicine ,Humans ,Hypertrophy, Left Ventricular ,General Medicine ,Cardiology and Cardiovascular Medicine ,Antihypertensive Agents ,Ventricular Function, Left - Published
- 2022
26. COVID-19 vaccination reduces mortality in patients on maintenance hemodialysis
- Author
-
Leszek Tylicki, Bogdan Biedunkiewicz, Ewelina Puchalska-Reglińska, Ryszard Gellert, Michel Burnier, Jacek Wolf, and Alicja Dȩbska-Ślizień
- Subjects
General Medicine - Abstract
Patients with chronic kidney disease on maintenance hemodialysis (HD) have a very high risk of death in the course of COVID-19. The aim of the study was to assess the effectiveness of COVID-19 vaccination to reduce the incidence of COVID-19 and the fatality rate in HD patients. A retrospective registry-based cohort study was performed in all HD adult patients in the Pomeranian Voivodeship. Vaccinations were carried out from January to April 2021 with mRNA vaccines, either BNT162b2 or mRNA-1273 with two-dose schedule. In the first analysis (2nd pandemic wave), 1,160 unvaccinated patients were included (59.7% males, 25.7% diabetic). In the second analysis (4th pandemic wave), 1,131 (59.4% male, 30.7% diabetic) individuals were included, 1,042 (92.13%) were fully vaccinated. Three hundred and fifteen HD patients (27.2%) were COVID-19 positive during the 2nd wave, and 6.9% (78/1,131) during the 4th wave. Within the fully vaccinated patients of the 4th wave, 60 were COVID-19 positive, 5.8 vs. 20.2% of unvaccinated COVID-19 positive patients in 2nd wave, respectively. COVID-19 incidence rate ratio (IRR) was 0.21 (4th wave-vaccinated vs. 2nd wave-unvaccinated) indicating a 79% reduction. The IRR between vaccinated and unvaccinated patients of the 4th wave was 0.28 in favor of vaccinated patients with 72% reduction. In the 2nd wave, 93 patients died as a result of COVID-19 (fatality rate: 29.5%). The fatality rate of fully vaccinated patients during the 4th wave was 6.7% (p = 0.004), while the fatality rate in the 4th wave within unvaccinated patients accounted for 11.1%. Significant clinical effectiveness of COVID-19 vaccination was demonstrated in a multicenter study in HD patients.
- Published
- 2022
27. Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage
- Author
-
Davide Bolignano, Graziella D'Arrigo, Alberto Ortiz, Grégoire Wuerzner, Jean-Michel Halimi, Alexandre Persu, Liffert Vogt, Gérard M. London, Ioannis N Boletis, Michel Burnier, Francesca Mallamaci, Patrick Rossignol, Nada Kanaan, Pantelis Sarafidis, Charalampos Loutradis, Bénédicte Sautenet, Carmine Zoccali, Anna Pisano, and Charles J. Ferro
- Subjects
Transplantation ,Creatinine ,medicine.medical_specialty ,Kidney ,education.field_of_study ,Ambulatory blood pressure ,business.industry ,End organ damage ,Population ,Renal function ,medicine.disease ,chemistry.chemical_compound ,medicine.anatomical_structure ,chemistry ,Nephrology ,Internal medicine ,Cardiology ,Medicine ,Circadian rhythm ,business ,education ,Kidney transplantation - Abstract
Background Few studies show that ambulatory blood pressure (BP) monitoring (ABPM) is superior to office BP (oBP) measurements to predict target organ damage and cardiovascular (CV) events in kidney transplant recipients (KTRs). We performed a systematic review aimed at determining the potential associations between BP recordings by different methods and renal and CV outcomes in this population. Methods Major medical databases were searched for studies enrolling adult KTRs undergoing 24-h ABPM compared with office or home BP measurements. The main outcomes were associations between different BP recordings and renal and CV outcomes. Additionally, any association between the circadian BP pattern (dipping/non-dipping status) and outcomes was assessed. Results Twenty-two studies (2078 participants) were reviewed. Among 12 studies collecting data on renal endpoints, 10 studies found that BP assessed by ABPM was a stronger predictor of renal function decline, assessed by serum creatinine and/or creatinine clearance or estimated glomerular filtration rate, than traditional office measurements. Twelve studies analysed the relation between different BP recordings and CV target organ damage and reported robust correlations between echocardiographic abnormalities (i.e. left ventricular mass index) and 24-h ABPM, but not with office BPs. Furthermore, 24-h ABPM correlated better than oBP with markers of vascular damage, such as carotid intima-media thickness, diffuse thickening and endothelial dysfunction. Additionally, an abnormal circadian BP pattern (non-dippers and reverse dippers) identified a group of kidney recipients at risk for kidney function loss and CV abnormalities. Conclusions In our systematic review, ABPM reflected target organ damage more closely than oBP in KTRs. Furthermore, an altered circadian BP profile associated with renal and CV target organ damage.
- Published
- 2021
28. Renal denervation for patients with chronic kidney disease and resistant hypertension: effective and safe but still not the panacea
- Author
-
Michel Burnier
- Subjects
Denervation ,Transplantation ,medicine.medical_specialty ,Ambulatory blood pressure ,biology ,business.industry ,Resistant hypertension ,Urology ,Renal function ,Kidney ,biology.organism_classification ,medicine.disease ,Nephrology ,Hypertension ,medicine ,Humans ,Renal Insufficiency, Chronic ,business ,Cardiovascular outcomes ,Panacea (butterfly) ,Kidney disease - Published
- 2021
29. The unsolved challenge of implementing sustained reductions of sodium intake in patients with chronic kidney disease
- Author
-
Michel Burnier, Denis Fouque, Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Hypertension Research Foundation [St-Légier, Switzerland] (HRF), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), and CarMeN, laboratoire
- Subjects
Transplantation ,medicine.medical_specialty ,business.industry ,[SDV]Life Sciences [q-bio] ,030232 urology & nephrology ,MEDLINE ,030204 cardiovascular system & hematology ,medicine.disease ,3. Good health ,Sodium intake ,[SDV] Life Sciences [q-bio] ,03 medical and health sciences ,0302 clinical medicine ,Nephrology ,Internal medicine ,medicine ,In patient ,business ,ComputingMilieux_MISCELLANEOUS ,Kidney disease - Abstract
International audience; No abstract available
- Published
- 2020
30. Water-Soluble Vitamin Levels and Supplementation in Chronic Online Hemodiafiltration Patients
- Author
-
Mohammed Benghezal, Roger Darioli, Michiko Kanemitsu, Sébastien Kissling, Michel Burnier, Serge Rezzi, Menno Pruijm, and Nora Schwotzer
- Subjects
Vitamin ,medicine.medical_specialty ,Vitamin C ,Dose ,business.industry ,medicine.medical_treatment ,030232 urology & nephrology ,Reference range ,030204 cardiovascular system & hematology ,Gastroenterology ,03 medical and health sciences ,chemistry.chemical_compound ,B vitamins ,0302 clinical medicine ,chemistry ,clearance ,hemodiafiltration ,hemodialysis ,vitamin B ,vitamin C ,Nephrology ,Internal medicine ,Medicine ,Water-Soluble Vitamin ,Hemodialysis ,business ,Dialysis - Abstract
Introduction Supplementation of water-soluble vitamins is a common practice in hemodialysis patients, but dosages are largely based on conventional hemodialysis techniques. The aim of this study was to assess the status of water-soluble vitamins in patients on hemodiafiltration (HDF), and attempt to determine optimal dose of vitamin supplements. Methods This monocentric study included 40 patients on thrice-weekly chronic HDF. At baseline, all patients received 2 tablets of Dialvit containing B and C vitamins after each dialysis session. Predialysis samples of B and C vitamins were measured in both blood (n = 40) and a subgroup of dialysate (n = 6) samples. A second blood sample was obtained in 24 patients 3 months after dose adjustment of the vitamin supplement. Results At baseline, B-vitamin levels were high with, respectively, 0.4%, 10.0%, and 89.6% of patients in the low, normal, and high reference range. For vitamin C, most patients were in the normal range (5.0%, 82.5%, and 12.5% in low, normal, and high reference range). Three months after dose reduction, B vitamin levels decreased but stayed mostly at or above the normal range (1.4%, 25.7%, 72.9% in low, normal, and high reference range). Three patients (12.5%) developed vitamin C deficiency on low-dose substititon. Conclusion This study shows that the levels of most vitamins are above the normal range in patients on HDF receiving a classic dose of vitamin supplements, vitamin C excepted. Our study suggests that the classic dose of postdialysis vitamin B supplements may be reduced.
- Published
- 2020
31. Hypertension management during the COVID-19 pandemic: what can we learn for the future?
- Author
-
Michel Burnier, Sverre E. Kjeldsen, Krzysztof Narkiewicz, Brent Egan, and Reinhold Kreutz
- Subjects
Hypertension ,Internal Medicine ,COVID-19 ,Humans ,General Medicine ,Cardiology and Cardiovascular Medicine ,Medical History Taking ,Pandemics - Published
- 2022
32. Contrast-Enhanced Ultrasound and Protein Shakes Are No Alternatives for Inulin Clearance and Meat to Assess Renal Functional Reserve in Humans
- Author
-
Aikaterini Damianaki, Wendy Brito, Jonas Garessus, Antoine Schneider, Marc Maillard, Michel Burnier, and Menno Pruijm
- Subjects
Male ,Meat ,Nephrology ,Inulin ,Animals ,Humans ,Female ,Kidney Diseases ,General Medicine ,Cardiology and Cardiovascular Medicine ,Kidney Function Tests ,Arginine ,Glomerular Filtration Rate - Abstract
Introduction: The measurement of renal functional reserve (RFR) can unmask glomerular hyperfiltration in residual nephrons, but its determination is time-consuming. In this study, we assessed whether contrast-enhanced ultrasound (CEUS) is a valuable alternative to the gold standard inulin clearance and whether L-arginine or protein shakes lead to similar changes in glomerular filtration rate (GFR) as animal proteins in men and women. Methods: Changes in GFR and renal microperfusion were studied in 25 healthy subjects (8 men, 17 women) by simultaneously performing inulin clearance and CEUS (perfusion index, PI) before and 1 and 2 h after different protein loads (L-arginine, protein shake or meat). The Doppler parameters – renal resistive index (RRI) and pulsatility index (PuI) – were also measured. Results: None of the oral protein loads induced significant changes in CEUS-assessed PI. Only meat increased inulin clearance (from 111.2 ± 16.0 to 149.8 ± 27.2 mL/min, p < 0.05) and mobilized RFR, while L-arginine decreased GFR (106.7 ± 45.3 to 86.3 ± 42.6 mL/min, p < 0.05). Protein shakes had a neutral effect. There were no correlations between changes in inulin clearance and PI. At Doppler, RRI and PuI increased after meat intake (from 0.647 ± 0.029 to 0.694 ± 0.050 a.u., p < 0.05 and from 1.130 ± 0.087 to 1.318 ± 0.163 a.u., p < 0.05, respectively), but their changes also did not correlate with changes in inulin clearance. Results were similar in both sexes. Conclusions: CEUS is not a valuable alternative for inulin clearance to measure RFR. Meat ingestion leads to modest changes in renal Doppler parameters and to glomerular hyperfiltration in both women and men, while protein shakes and L-arginine do not.
- Published
- 2022
33. Partnership between patients and interprofessional healthcare providers along the multifaceted journey to medication adherence
- Author
-
Marie P. Schneider and Michel Burnier
- Subjects
Pharmacology ,Pharmacology (medical) - Published
- 2022
34. Néphrologie: que s’est-il passé ces 20 dernières années ?
- Author
-
Michel Burnier
- Published
- 2022
35. Impact of kidney transplantation on sleep apnea severity: A prospective polysomnographic study
- Author
-
José Haba-Rubio, Jean-Pierre Venetz, Valentina Forni Ogna, Délaviz Golshayan, Maurice Matter, Raphael Heinzer, Adam Ogna, Grzegorz Nowak, Manuel Pascual, and Michel Burnier
- Subjects
medicine.medical_specialty ,Polysomnography ,Body water ,Renal function ,030230 surgery ,Gastroenterology ,03 medical and health sciences ,Sleep Apnea Syndromes ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Immunology and Allergy ,Pharmacology (medical) ,Prospective Studies ,Prospective cohort study ,Kidney transplantation ,Hydration status ,Transplantation ,Kidney ,business.industry ,Sleep apnea ,medicine.disease ,Kidney Transplantation ,medicine.anatomical_structure ,Kidney Failure, Chronic ,business ,Kidney disease - Abstract
Fluid overload has been associated with a high prevalence of sleep apnea (SA) in patients with end-stage kidney disease (ESKD). In this prospective study, we hypothesized that improvement in kidney function and hydration status after kidney transplantation (Tx) may result in an improvement in SA severity. A total of 196 patients on the kidney Tx waiting list were screened for SA using home nocturnal polysomnography (PSG) to measure the apnea-hypopnea index (AHI) and underwent bioimpedance to assess body composition. Of 88 participants (44.9%) with SA (AHI ≥ 15/h), 42 were reassessed 6 months post-Tx and were compared with 27 control patients. There was a significant, but small, post-Tx improvement in AHI (from 44.2 ± 24.3 to 34.7 ± 20.9/h, P = .02) that significantly correlated with a reduction in fluid overload (from 1.8 ± 2.0 to 1.2 ± 1.2 L, P = .02) and body water (from 54.9% to 51.6%, P = .003). A post-Tx increase in body fat mass (from 26% to 30%, P = .003) possibly blunted the beneficial impact of kidney Tx on SA. All parameters remained unchanged in the control group. In conclusion, SA is a frequent condition in ESKD patients and partially improved by kidney Tx. We suggest that SA should be systematically assessed before and after kidney Tx. ClinicalTrials.gov Identifier: NCT02020642.
- Published
- 2020
36. Short-term changes in dietary sodium intake influence sweat sodium concentration and muscle sodium content in healthy individuals
- Author
-
Nicolas Loncle, Menno Pruijm, Bastien Milani, Matthias Stuber, Jean Delacoste, Joao Miguel Lourenco, Wendy Brito, Philippe Braconnier, Marc Maillard, and Michel Burnier
- Subjects
Adult ,Male ,medicine.medical_specialty ,Normal diet ,Physiology ,Sodium ,chemistry.chemical_element ,Blood Pressure ,030204 cardiovascular system & hematology ,Plasma renin activity ,Urine sodium ,SWEAT ,Young Adult ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Internal Medicine ,medicine ,Humans ,030212 general & internal medicine ,Salt intake ,Muscle, Skeletal ,Sweat ,Aldosterone ,Cross-Over Studies ,business.industry ,Sodium, Dietary ,Middle Aged ,Endocrinology ,chemistry ,Pilocarpine ,Female ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
OBJECTIVE There is increasing evidence that sodium can be stored in the skin and muscles without being osmotically active, yet whether acute changes in dietary sodium intake alter sweat and muscle sodium content has not been investigated previously. METHODS In a cross-over design, we assessed muscle sodium content by Na-MRI in 38 healthy normotensive volunteers (aged 33.5 ± 11.1 years, 76.3% women) after 5 days of high-sodium diet (6 g of salt added to their normal diet) and 5 days of a low-sodium diet. In a subgroup of 18 participants (72.2% women) we conducted quantitative pilocarpine iontophoretic sweat collections and measured the sodium concentration in sweat. Plasma aldosterone and plasma renin activity levels were measured in all participants. RESULTS Under high-sodium diet conditions urinary sodium excretion, muscle sodium content and sweat sodium concentration all increased significantly. Muscle sodium content (rm = 0.47, P = 0.03) and sodium sweat concentration (rm = 0.72, P
- Published
- 2020
37. A 30th anniversary and a glimpse of the future
- Author
-
Michel Burnier and Sverre E. Kjeldsen
- Subjects
Anniversaries and Special Events ,Internal Medicine ,Humans ,General Medicine ,History, 20th Century ,Cardiology and Cardiovascular Medicine - Published
- 2022
38. Nutritional management of sodium, chloride, and water in kidney disease and kidney failure
- Author
-
Michel Burnier
- Subjects
Kidney ,business.industry ,Sodium ,medicine.medical_treatment ,chemistry.chemical_element ,Physiology ,medicine.disease ,Excretion ,medicine.anatomical_structure ,chemistry ,medicine ,Polycystic kidney disease ,Kidney stones ,business ,Homeostasis ,Dialysis ,Kidney disease - Abstract
The regulation of salt and water balance is one the most important and complex physiological processes enabling to maintain homeostasis of the extracellular and intracellular volumes in health as well as in disease conditions. This regulatory process is mediated by multiple factors influencing both the intake of sodium and water and their excretion, essentially by the kidney. In recent years, new mechanisms of regulation of sodium and water balance have been described demonstrating tissue accumulation in the skin and muscles. This has changed substantially the usual concepts of how sodium and water are handled involving not only new storage compartments but also new regulatory pathways such as the immune system and inflammation. There is now evidence that these new mechanisms play also an important role also in patients with chronic kidney disease (CKD) or kidney failure as it will be discussed in this chapter. In patients with kidney diseases, a reduction in sodium intake and an adequate water intake are always two major components of the nutritional management. Indeed, on a lower sodium diet, blood pressure and proteinuria decrease and there is weak evidence suggesting that renal disease progression may be delayed. Today, most recommendations propose a sodium intake between 2 and 2.3 g Na/day (5–6 g NaCl) in CKD patients. Daily oral fluid intake should be between 1500 and 2000 mL/day in most CKD patients, except those on dialysis who should drink less and those with specific renal diseases such kidney stone diseases and polycystic kidney disease, who need to have a very high urine output.
- Published
- 2022
39. List of contributors
- Author
-
Marcin Adamczak, Maria Ida Amabile, Ibironke W. Apata, Mugurel Apetrii, Carla Maria Avesani, Udo Bahner, James L. Bailey, Anip Bansal, Christophe Barba, Ezequiel Bellorin-Font, Rachelle Bross, Amanda Brown-Tortorici, Michel Burnier, Jerrilynn Denise Burrowes, Juan Jesús Carrero, MacKenzie K. Cervantes, Steven Chadban, Vimal Chadha, Maria Chan, Winnie Chan, Charles Chazot, Janet M. Chiang, Michel Chonchol, Lydia Chwastiak, Adrian Covic, Lilian Cuppari, Neera K. Dahl, Biagio Di Iorio, Francesca Di Mario, Wilfred Druml, Ramanath Dukkipati, Gholamreza Fazeli, Enrico Fiaccadori, Fredric Finkelstein, Denis Fouque, Harold A. Franch, Allon N. Friedman, Pranav S. Garimella, Richard J. Glassock, David S. Goldfarb, Ailema González-Ortiz, Nimrit Goraya, Orlando M. Gutiérrez, Norio Hanafusa, August Heidland, Olof Heimbürger, Raimund Hirschberg, T. Alp Ikizler, Kirsten Johansen, Richard J. Johnson, Shivam Joshi, Kamyar Kalantar-Zadeh, Duk-Hee Kang, George A. Kaysen, Jun-Chul Kim, Brandon Kistler, Laetitia Koppe, Joel D. Kopple, Csaba P. Kovesdy, Holly J. Kramer, Kiyoshi Kurokawa, Bengt Lindholm, Kevin J. Martin, Steve Martino, Stefania Marzocco, Shaul G. Massry, Ziad A. Massy, William E. Mitch, Toshio Miyata, Alessio Molfino, Hamid Moradi, Takahiko Nakagawa, Yoko Narasaki, Nancy Puzziferri, Noel Quinn, Dominic S. Raj, Kalani L. Raphael, Renu Regunathan-Shenk, Connie M. Rhee, Eberhard Ritz, Alice Sabatino, Mark J. Sarnak, Julia Scialla, Lothar Seefried, John Sellinger, Anuja Shah, Neal B. Shah, Sudhir V. Shah, Manisha Singh, Leonardo Spatola, Robert C. Stanton, Alison L. Steiber, Peter Stenvinkel, David E. St-Jules, Thomas W. Storer, Keiichi Sumida, Elizabeth J. Sussman-Dabach, Sundararaman Swaminathan, John Sy, Ekamol Tantisattamo, Nosratola D. Vaziri, Alexandra Voinescu, Angela Yee-Moon Wang, Bradley A. Warady, Daniel E. Weiner, Donald E. Wesson, Andrzej Wiecek, Mark E. Williams, Bruce M. Wolfe, Biruh T. Workeneh, and Ying-Yong Zhao
- Published
- 2022
40. Parathyroid Hormone and Plasma Phosphate Are Predictors of Soluble α-Klotho Levels in Adults of European Descent
- Author
-
Daniel Ackermann, Menno Pruijm, Daniel Guido Fuster, Michel Burnier, Bruno Vogt, Johanne Pastor, Nasser A. Dhayat, Georg Martin Fiedler, Pierre-Yves Martin, Idris Guessous, Belen Ponte, Olivier Devuyst, Georg Ehret, Alexander Benedikt Leichtle, Antoinette Pechère-Bertschi, Murielle Bochud, Orson W. Moe, and University of Zurich
- Subjects
Male ,Fibroblast growth factor 23 ,1303 Biochemistry ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,030232 urology & nephrology ,Parathyroid hormone ,Urine ,1308 Clinical Biochemistry ,urologic and male genital diseases ,medical ,Biochemistry ,10052 Institute of Physiology ,chemistry.chemical_compound ,0302 clinical medicine ,Endocrinology ,Glucuronidase ,Aged, 80 and over ,ddc:616 ,2. Zero hunger ,Minerals ,0303 health sciences ,education.field_of_study ,Middle Aged ,Prognosis ,female genital diseases and pregnancy complications ,1310 Endocrinology ,Diabetes and Metabolism ,2712 Endocrinology, Diabetes and Metabolism ,Parathyroid Hormone ,Fibroblast growth factor receptor ,Female ,Soluble α-klotho ,Adult ,Vitamin ,medicine.medical_specialty ,Adolescent ,Population ,Renal function ,610 Medicine & health ,Phosphate ,2704 Biochemistry (medical) ,White People ,Phosphates ,Young Adult ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Online Only Articles ,education ,Klotho Proteins ,Aged ,ddc:613 ,030304 developmental biology ,Biochemistry (medical) ,Fibroblast Growth Factor-23 ,Cross-Sectional Studies ,chemistry ,570 Life sciences ,biology ,Biomarkers ,Follow-Up Studies ,Hormone - Abstract
Context α-klotho is an integral membrane protein that serves as a coreceptor for fibroblast growth factor 23 (FGF23) in conjunction with cognate fibroblast growth factor receptors. Proteolytic cleavage sheds the ectodomain of α-klotho (soluble α-klotho) as an endocrine substance into blood, urine, and cerebrospinal fluid. Objective To study the relationship of soluble α-klotho to mineral metabolism in the general population with mainly preserved kidney function. Design Cross-sectional analysis of the associations between soluble α-klotho with laboratory markers of markers of mineral metabolism in a population-based cohort. Setting Three centers in Switzerland including 1128 participants. Measures Soluble full-length α-klotho levels by a specific immunoassay and markers of mineral metabolism. Results The median serum level of soluble α-klotho was 15.0 pmol/L. Multivariable analyses using α-klotho as the outcome variable revealed a sex-by-PTH interaction: In men, PTH was positively associated with α-klotho levels, whereas this association was negative in women. Plasma phosphate associated with soluble α-klotho levels in an age-dependent manner, changing from a positive association in young adults gradually to a negative association in the elderly. The decline of 1,25 (OH)2 vitamin D3 levels in parallel to the gradual impairment of kidney function was greatly attenuated in the setting of high circulating soluble α-klotho levels. Conclusions Soluble α-klotho level is associated with plasma phosphate in an age-dependent manner and with PTH in a sex-dependent manner. Furthermore, our data reveal soluble α-klotho as a modulator of 1,25 (OH)2 vitamin D3 levels in individuals with preserved renal function.
- Published
- 2019
41. New Aspects in the Management of Hypertension in Patients with Chronic Kidney Disease not on Renal Replacement Therapy
- Author
-
Aikaterini Damianaki, Erietta Polychronopoulou, Gregoire Wuerzner, and Michel Burnier
- Subjects
Renal Replacement Therapy ,Hypertension ,Internal Medicine ,Humans ,Blood Pressure ,Renal Insufficiency, Chronic ,Cardiology and Cardiovascular Medicine ,Antihypertensive Agents - Abstract
With chronic kidney disease (CKD) being a global arising health problem, strategies for delaying kidney disease progression and reducing the high cardiovascular risk inherent to CKD, are the main objectives of the actual management of patients with kidney diseases. In these patients, the control of arterial hypertension is essential, as high blood pressure (BP) is a strong determinant of worst cardiovascular and renal outcomes. Achieving target blood pressures recommended by international guidelines is mandatory and often demands a multiple levels management, including several pharmacological and lifestyle measures. Even in the presence of adequate BP control, the residual cardiovascular risk remains high. In this respect, the recent demonstration that novel agents such as sodium glucose transporter 2 (SGLT2) inhibitors or the new non-steroidal mineralocorticoid antagonist finerenone can retard the progression of kidney diseases and reduce cardiovascular mortality on top of standard of care treatment with renin-angiotensin system inhibitors represent enormous progresses. These studies also demonstrate that cardiovascular and renal protection can be obtained beyond blood pressure control. Other promising novelties are still to come such as renal denervation and endothelin receptor antagonists in the setting of diabetic and non-diabetic kidney diseases. In the present review, we shall discuss the classic and the new aspects for the management of hypertension in CKD, integrating the new data from recent clinical studies.
- Published
- 2021
42. BLOOD PRESSURE AWARENESS AND CONTROL IN SWISS PHARMACIES DURING MMM17–18 CAMPAIGNS
- Author
-
Katerina Damianaki, Gerald Menetre, Michel Burnier, and Gregoire Wuerzner
- Subjects
Physiology ,Internal Medicine ,Cardiology and Cardiovascular Medicine - Published
- 2022
43. Sex differences in the progression of kidney injury and risk of death in CKD patients: is different ambulatory blood pressure control the underlying cause?
- Author
-
Pantelis Sarafidis and Michel Burnier
- Subjects
Male ,Sex Characteristics ,Transplantation ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Ambulatory blood pressure ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,MEDLINE ,Blood Pressure ,Blood Pressure Monitoring, Ambulatory ,Kidney ,Text mining ,Nephrology ,Internal medicine ,Hypertension ,medicine ,Kidney injury ,Humans ,Female ,Risk of death ,Renal Insufficiency, Chronic ,business - Published
- 2021
44. Changes of lipoprotein(a) levels with endogenous steroid hormones
- Author
-
Kevin Dobretz, Bruno Vogt, Elena Tessitore, Nicolas Vuilleumier, Menno Pruijm, Murielle Bochud, Daniel Ackermann, Nasser A. Dhayat, Ilse Kern, Pierre-Yves Martin, Belen Ponte, Sandrine Estoppey, François Mach, Michel Burnier, and Georg Ehret
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Clinical Biochemistry ,Population ,610 Medicine & health ,Biochemistry ,Cohort Studies ,chemistry.chemical_compound ,Lipoprotein (a) ,Internal medicine ,medicine ,Humans ,Endogenous hormones ,Prospective Studies ,education ,Prospective cohort study ,Aged ,ddc:616 ,education.field_of_study ,Androsterone ,biology ,business.industry ,Estriol ,General Medicine ,Lipoprotein(a) ,Middle Aged ,Cardiovascular risk ,Hormones ,Steroid hormone ,Endocrinology ,chemistry ,biology.protein ,Female ,business ,Lipoprotein ,Hormone - Abstract
Background: Lipoprotein(a) [Lp(a)] is an LDL-like molecule that is likely causal for cardiovascular events and Lp(a) variability has been shown to be mostly of genetic origin. Exogenous hormones (hormone replacement therapy) seem to influence Lp(a) levels, but the impact of endogenous hormone levels on Lp(a) is still unknown. The aim of the study was to assess the effect of endogenous steroid hormone metabolites on Lp(a). Methods: Lipoprotein(a) levels were measured in 1,021 participants from the Swiss Kidney Project on Genes in Hypertension, a family-based, multicentre, population-based prospective cohort study. Endogenous levels of 28 steroid hormone precursors were measured in 24-h urine collections from 883 individuals. Of the participants with Lp(a) data, 1,011 participants had also genotypes available. Results: The participants had an average age of 51 years and 53% were female. Median Lp(a) levels were 62 mg/L, and the 90thpercentile was 616 mg/L. The prevalence of a Lp(a) elevation ≥700 mg/L was 3.2%. Forty-three per cent of Lp(a) variability was explained respectively by: age (2%, p-16). Of the 28 endogenous steroid hormones assessed, androstenetriol, androsterone, 16α-OH-DHEA and estriol were nominatively associated with serum Lp(a) levels in univariable analyses and explained 0.4%-1% of Lp(a) variability, but none of them reached significance in multivariable models. Conclusions: In this contemporary population-based study, the prevalence of a Lp(a) elevation ≥700 mg/L was 3.2%. The effect of endogenous steroid hormone levels of Lp(a) variability was small at best, suggesting a negligible impact on the wide range of Lp(a) variability.
- Published
- 2021
45. Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers
- Author
-
Suzanne Oparil, Michel Burnier, Krzysztof Narkiewicz, and Sverre E. Kjeldsen
- Subjects
2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Adrenergic receptor ,business.industry ,General Medicine ,030204 cardiovascular system & hematology ,Pharmacology ,Overweight ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Diabetes mellitus ,Renin–angiotensin system ,Pandemic ,Internal Medicine ,Medicine ,In patient ,030212 general & internal medicine ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business - Abstract
From the beginning of the pandemic hypertension appeared as one of the most common comorbidities in patients hospitalised with a Covid-19 infection. Hypertension, diabetes, overweight, chronic pulm...
- Published
- 2020
46. Was it optimal to drop a diuretic as a first-line choice of drug treatment in the 2020 International Society of Hypertension Guidelines?
- Author
-
Sverre E. Kjeldsen, Suzanne Oparil, Krzysztof Narkiewicz, and Michel Burnier
- Subjects
medicine.medical_specialty ,business.industry ,First line ,medicine.medical_treatment ,MEDLINE ,General Medicine ,030204 cardiovascular system & hematology ,03 medical and health sciences ,Drug treatment ,0302 clinical medicine ,Blood pressure ,Pharmaceutical Preparations ,Hypertension ,Internal Medicine ,medicine ,Humans ,030212 general & internal medicine ,Diuretic ,Diuretics ,Medical History Taking ,Cardiology and Cardiovascular Medicine ,Intensive care medicine ,business ,Antihypertensive Agents - Abstract
In this issue of Blood Pressure, the lead authors of the 2020 International Society of Hypertension (ISH) Guidelines comment [1] on our recent editorial [2] regarding their first choice of antihype...
- Published
- 2020
47. Cuff-less measurements of blood pressure: are we ready for a change?
- Author
-
Sverre E. Kjeldsen, Suzanne Oparil, Krzysztof Narkiewicz, and Michel Burnier
- Subjects
medicine.medical_specialty ,business.industry ,Blood Pressure ,Blood Pressure Determination ,General Medicine ,humanities ,Blood pressure ,Internal medicine ,Oscillometry ,Cuff ,Internal Medicine ,medicine ,Cardiology ,Humans ,Cardiology and Cardiovascular Medicine ,business - Abstract
The first non-invasive measurements of arterial blood pressure (BP) became possible in the middle of the nineteenth century when Vierodt had the idea to quantify arterial BP by measuring the pressu...
- Published
- 2021
48. Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis
- Author
-
Liffert Vogt, Graziella D'Arrigo, Alexandre Persu, Charalampos Loutradis, Davide Bolignano, Ioannis N Boletis, Bénédicte Sautenet, Grégoire Wuerzner, Francesca Mallamaci, Alberto Ortiz, Nada Kanaan, Michel Burnier, Pantelis Sarafidis, Patrick Rossignol, Gérard M. London, Anna Pisano, Charles J. Ferro, Jean-Michel Halimi, Carmine Zoccali, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (MGD) Service de néphrologie, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, Institute of Clinical Physiology, CNR, Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Universidad Autónoma de Madrid (UAM), Université Catholique de Louvain = Catholic University of Louvain (UCL), Cliniques Universitaires Saint-Luc [Bruxelles], Aristotle University of Thessaloniki, Hippokration Hospital, University Hospitals Birmingham [Birmingham, Royaume-Uni], University of Athens Medical School [Athens], Centre Hospitalier Manhès [Fleury-Mérogis], Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR des Sciences Pharmaceutiques et Biologiques (Nantes Université - UFR Pharmacie), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Université de Tours (UT), Nantes Université (Nantes Univ), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Amsterdam UMC - Amsterdam University Medical Center, and BOZEC, Erwan
- Subjects
Transplantation ,medicine.medical_specialty ,Ambulatory blood pressure ,hypertension ,business.industry ,kidney transplantation ,medicine.disease ,CKJ Review ,[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,meta-analysis ,ambulatory blood pressure monitoring ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,systematic review ,Nephrology ,Meta-analysis ,Emergency medicine ,Medicine ,cardiovascular diseases ,business ,AcademicSubjects/MED00340 ,Kidney transplantation - Abstract
Background Hypertension (HTN) is common following renal transplantation and it is associated with adverse effects on cardiovascular (CV) and graft health. Ambulatory blood pressure monitoring (ABPM) is the preferred method to characterize blood pressure (BP) status, since HTN misclassification by office BP (OBP) is quite common in this population. We performed a systematic review and meta-analysis aimed at determining the clinical utility of 24-h ABPM and its potential implications for the management of HTN in this population. Methods Ovid-MEDLINE and PubMed databases were searched for interventional or observational studies enrolling adult kidney transplant recipients (KTRs) undergoing 24-h ABP readings compared with OBP or home BP. The main outcome was the proportion of KTRs diagnosed with HTN by ABPM, home or OBP recordings. Additionally, day–night BP variability and dipper/non-dipper status were assessed. Results Forty-two eligible studies (4115 participants) were reviewed. A cumulative analysis including 27 studies (3481 participants) revealed a prevalence of uncontrolled HTN detected by ABPM of 56% [95% confidence interval (CI) 46–65%]. The pooled prevalence of uncontrolled HTN according to OBP was 47% (95% CI 36–58%) in 25 studies (3261 participants). Very few studies reported on home BP recordings. The average concordance rate between OBP and ABPM measurements in classifying patients as controlled or uncontrolled hypertensive was 66% (95% CI 59–73%). ABPM revealed HTN phenotypes among KTRs. Two pooled analyses of 11 and 10 studies, respectively, revealed an average prevalence of 26% (95% CI 19–33%) for masked HTN (MHT) and 10% (95% CI 6–17%) for white-coat HTN (WCH). The proportion of non-dippers was variable across the 28 studies that analysed dipping status, with an average prevalence of 54% (95% CI 45–63%). Conclusions In our systematic review, comparison of OBP versus ABP measurements disclosed a high proportion of MHT, uncontrolled HTN and, to a lesser extent, WCH in KTRs. These results suggest that HTN is not adequately diagnosed and controlled by OBP recordings in this population. Furthermore, the high prevalence of non-dippers confirmed that circadian rhythm is commonly disturbed in KTRs.
- Published
- 2021
49. Obituary for Norman K. Hollenberg, M.D., PhD. (1936-2020)
- Author
-
Michel Burnier and Murray Epstein
- Subjects
Physiology ,business.industry ,Internal Medicine ,Medicine ,Obituary ,Theology ,Cardiology and Cardiovascular Medicine ,business - Published
- 2020
50. Estimated 24-h urinary sodium and sodium-to-potassium ratio are predictors of kidney function decline in a population-based study
- Author
-
Idris Guessous, Belen Ponte, Olivier Devuyst, Peter Vollenweider, Denis Deriaz, Murielle Bochud, Michel Burnier, and University of Zurich
- Subjects
Male ,Physiology ,030204 cardiovascular system & hematology ,Kidney ,Kidney Function Tests ,10052 Institute of Physiology ,Cohort Studies ,0302 clinical medicine ,Risk Factors ,Renal Insufficiency ,030212 general & internal medicine ,education.field_of_study ,medicine.diagnostic_test ,Middle Aged ,medicine.anatomical_structure ,Disease Progression ,Female ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,Glomerular Filtration Rate ,Adult ,medicine.medical_specialty ,Urinalysis ,Sodium ,Population ,Urology ,chemistry.chemical_element ,Renal function ,610 Medicine & health ,2705 Cardiology and Cardiovascular Medicine ,03 medical and health sciences ,Internal Medicine ,medicine ,Albuminuria ,Humans ,Renal Insufficiency, Chronic ,education ,business.industry ,Sodium, Dietary ,1314 Physiology ,medicine.disease ,Confidence interval ,chemistry ,2724 Internal Medicine ,Potassium ,570 Life sciences ,biology ,business ,Kidney disease - Abstract
BACKGROUND: The prevalence of chronic kidney disease (CKD) is increasing worldwide in part due to population ageing. Identifying risk factors for age-related kidney function decline could help in understanding mechanisms for kidney ageing. Sodium and potassium intakes are associated with CKD progression in the renal population, but little is known on their role in renal function decline [mean estimated glomerular filtration rate variation (ΔeGFR)] in the general adult population. METHOD: We therefore explored the association of urinary sodium and potassium excretions with ΔeGFR in a longitudinal population-based cohort. We estimated 24-h urinary sodium (eUNa), potassium (eUK) and sodium-to-potassium ratio (eUNa/K) from spot urine using Kawasaki formulae. We performed multivariate linear regression models studying the association of eUNa, eUK and eUNa/K with yearly ΔeGFR, taking several covariates into account, including baseline eGFR and albuminuria. RESULTS: There were 4141 white participants from which 54.3% were women. Median age was 51.5 [43.6-60.6] years and mean baseline eGFR 88 (SD 15) ml/min per 1.73 m. During a median follow-up of 5.4 years, mean ΔeGFR was -0.59 (SD 1.68) ml/min per 1.73 m per year. In the fully adjusted model, high eUNa and eUNa/K were associated with faster renal function decline with standardized coefficients β = -0.07 (95% confidence interval: -0.11 to -0.04) and β = -0.05 (95% confidence interval: -0.08 to -0.02), respectively. By contrast, eUK, taken alone, showed no association. CONCLUSION: These results suggest that dietary sodium and potassium intakes may play a role in kidney function decline in the general adult population. Whether lowering sodium and increasing potassium in the diet may help in CKD prevention needs further exploration.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.